SEARCH
Tynax ~ Patent Library

Patent for Sale:

Innovative Formulations in the Area of Chronotherapeutic Drug Delivery    

Products/IP enable drug delivery to be targeted for optimum release time or location, thus providing a rational approach for treating disease while at the same time improving both efficacy & safety

Overview

Strong intellectual property portfolio in the areas of targeted and chronotherapeutic drug delivery with a pipeline of novel product opportunities. The primary focus of activities has been in the high value cardiovascular and CNS therapeutic areas. The cardiovascular offering focuses on novel statin formulations, which should improve the therapeutic index of current statin treatment and SR low dose statins with applicability to special patient populations/OTC use. In the pain arena, the company has developed a delayed release long acting, once daily, formulation of Tramadol for the treatment of moderate to severe pain.

STATIN FORMULATION - The concept underlying this formulation involves controlling the amount and rate of statin delivered to the liver from the gut. This approach should provide the following benefits compared with standard statin administration: (i) improved therapeutic window, (ii) enhanced lipid-lowering efficacy of lower potency statins, (ii) higher doses of statin to achieve maximal lipid lowering effects without associated increase in systemic exposure, (iv) decreased variability in plasma bioavailability compared to standard statins, and (v) differentiated product with potential for premium pricing.

The global statin market currently exceeds $20 billion per annum. Combination statin therapy comprises over 15% of the US market and is growing rapidly. The Company believes statin formulations will have significant revenue potential based on the ability to enhance the competitiveness of statins by increasing therapeutic index of existing molecules and improving tolerability enabling wider use of combination products and an enhanced OTC opportunity.

TRAMADOL FORMULATION - This novel approach has the ability to carve out a niche market providing significant patient benefits: (i) targets morning pain management along with extended coverage for the remainder of the day, (ii) due to night time “drug free period”, helps minimize tolerance, rebound and night time dizziness, and disorientation, (iii) administered in capsules, or with the potential to be sprinkled on food, or dosed with enteral feed, and (iv) minimizes the risk of patients waking up in pain needing to take a medication and then waiting for pain relief to commence.

Globally, the pain management market is valued in excess of $50 billion, growing at 10% (IMS 2013). In the US alone, the market for opioid analgesics is $8.3 billion - 50% of this market is dominated by extended release opioids. The tramadol market is growing due to its safety advantages over other pain medications and its extensive use by primary care physicians compared with other opioids.

Primary Application of the Technology

Pharmaceutical

The seller may consider selling these patents individually.

Additional Information

Full data packages for pre‐clinical and clinical work conducted by the seller are available for review. Click 'Tell Me More' and request this information.

Patent Summary

U.S. Patent Classes & Classifications Covered in this listing:

Class 514: Drug, Bio-Affecting And Body Treating Compositions

This class is an integral part of Class 424. It includes the following subject matter, not provided for elsewhere: 1. Drug and bio-affecting compositions which are capable of: preventing, alleviating, treating, or curing abnormal and pathological conditions of the living body; maintaining, increasing, decreasing, limiting, or destroying a physiologic body function; diagnosing a physiological condition or state by an in vivo test; controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or micro-organism. 2. Body treating compositions generally intended for deodorizing, protecting, adorning, or grooming a body. 3. Fermentates. Plant and animal extracts, or body fluids or material containing plant or animal cellular structure. 4. Compositions of this class defined in terms of specific structure; e.g., layered tablet, capsule. 5. Processes of using or preparing subject matter of the Class Definition.

Subclass 275: Nitrogen bonded directly to the 1,3-diazine at 2-position by a single bond
Subclass 423: C=X bonded directly to the five-membered hetero ring by nonionic bonding (X is chalcogen)
Subclass 427: Two double bonds between ring members of the five-membered hetero ring (e.g., pyrrole, etc.)
Subclass 460: Chalcogen bonded directly to ring carbon of the hetero ring
Subclass 510: Polycyclo ring system
Subclass 547: Compound contains two or more C(=O)O groups
Subclass 548: Ring is alcohol moiety
Subclass 708: Oxygen bonded directly to sulfur (e.g., sulfoxides, etc.)

Class 548: Organic Compounds -- Part Of The Class 532 Series

The classes of the 532 series embrace monomeric organic carbon compounds and polymeric organic carbon compounds that are not solid synthetic resins, natural rubbers, or hydrocarbons.

Subclass 537: Acyclic nitrogen bonded directly to the -C(=X)- (e.g., 4,5-dihalopyrrole -2 carboxamides, etc.)